-
How to deal with the most common cancers in the world? Please collect this list
Time of Update: 2023-01-05
The US FDA approved it as an extended adjuvant therapy for patients with HER2-positive early-stage breast cancer, and in 2020 further expanded its indication to combine the chemotherapy drug capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have previously received at least 2 anti-HER2 regimens.
-
A full inventory of domestic gene therapy companies
Time of Update: 2023-01-05
Global gene therapy has started, in recent years, domestic gene therapy companies have appeared frequently, what stage has domestic gene therapy developed? We studied the basic situation of more than
-
Hengrui surpassed Pfizer to the fourth in the world, AZ ranked TOP1 in a row, and Novartis entered Phase III the most! Global clinical trials show these trends!
Time of Update: 2023-01-05
In 2021, the number of phase I-III trials ranked among the top 10 industry sponsors/partnersPharma According to Intelligence's 2021 Clinical Trials Review, more studies were initiated in China in 2021 than in any other country, while the clinical trial activities of large pharmaceutical companies focused on solid tumors and showed a trend of increasing R&D focus.
-
Chinese medicine pieces were collected for the first time (15 provinces/regions), and the rule catalogue was analyzed
Time of Update: 2023-01-05
Author: Zhang Tingjie When the highest effective declared price of different product specifications of the same variety does not match the quality level, in principle, the first round of quotations of the shortlisted enterprises of the selection review team shall be referred to, and the review experts shall unify them The maximum effective declared price of the cargo review team is adjusted.
-
Vigorously promote the development of the biomedical industry, and release 2025 goals in many places!
Time of Update: 2023-01-05
【Pharmaceutical Network Policies and Regulations】With the in-depth development of a new round of scientific and technological revolution and industrial transformation, the global life sciences are cha
-
Outbreak of rare disease drugs: In the past two years, 14 have been included in medical insurance and 13 have been approved for marketing
Time of Update: 2023-01-05
On June 10, 2020, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China announced that the new drug application for the SMN2 gene splicing regulator risdiplam oral solution powder proposed to treat spinal muscular atrophy will be included in the priority review.
-
51 varieties are coming! 600 million market reshuffle, stone medicine, Luo Xin... Successfully break through, the country of biological medicine is approaching step by step?
Time of Update: 2023-01-05
On November 16, the results of the proposed selection of drugs in Hebei Province, which lasted for half a month, were officially announced, with a total of 51 varieties (98 drugs) to be selected, involving 74 manufacturers, including the exclusive anticancer drug elemi injection of CSPC Pharmaceutical Group, rabeprazole sodium for injection for non-medical gastric ulcer treatment drug of Shandong Luoxin Pharmaceutical, and oxacillin sodium for injection of star antibacterial drug of Beite Pharmaceutical.
-
Local ADC inventory: HER2, TROP2 are the most crowded, Hengrui, CSPC, Kelun, East China Medicine and other in-depth layout!
Time of Update: 2023-01-05
HER2 and TROP2 are the most crowdedHER2 and TROP2 are the most crowdedTarget clustering is a common phenomenon of global research and development, and this phenomenon is even more so in domestic ADC new drugs, according to statistics, 22 ADC drugs targeting the "number one target" HER2 have been announced in China, accounting for 26% of all products.
-
K drug apocalypse: 13 innovative drugs give up medical insurance, still red flags flutter?
Time of Update: 2023-01-05
2022 is a special year for Merck's PD-1 pembrolizumab (known as "K drug"). In 2022Q1, K drug surpassed Humira, the first blockbuster drug for ten consecutive years, with sales reaching US$4. 809 billi
-
Merck acquires Imago for $1.35 billion to expand its blood disease pipeline
Time of Update: 2023-01-05
”English: _mstmutation="1" _msthash="220727" _msttexthash="1963325"> Merck announced on November 21 that it will acquire Imago through its subsidiary for $36 per share in cash BioSciences, with a total transaction value of approximately $1.
-
First! FDA approves gene therapy for adult hemophilia
Time of Update: 2023-01-05
(FIX)Today's approved Hemgenix uses AAV5 vectors to deliver coagulation factor IX Transgenic of the Padua variant, which is 5-8 times more active than ordinary coagulation factor IX, can complete normal coagulation function at lower expression levels.
-
Head-to-head challenges win, but fight poison with poison. Can excellent clinical data turn psychedelics around?
Time of Update: 2023-01-05
On November 23, 2022, Johnson & Johnson subsidiary Janssen released new Phase 3 clinical data for the antidepressant drug Spravato.
(same as freehand) On November 23, 2022, Johnson & Johnson subsidiary Janssen released new Phase 3 clinical data for the antidepressant drug Spravato.
-
The stock price crashed by 70%! Will this Biotech go bankrupt?
Time of Update: 2023-01-05
Rubraca is the second PARP inhibitor to be marketed in the world, originally developed by Pfizer and later transferred to Clovis, and its only commercial product.
Rubraca is the second PARP inhibitor to be marketed in the world, originally developed by Pfizer and later transferred to Clovis, and its only commercial product.
-
Discussion on the positioning of rare disease catalogue and the improvement of drug innovation and accessibility
Time of Update: 2023-01-05
com Review proofreader: Zhang Zhijuan, Liu Fapeng Review proofreader: Zhang Zhijuan, Liu Fapeng In the face of the current problems such as import dependence of rare disease drugs, payment dilemma, and obstruction of access to medical institutions, it is necessary to form a "three-drug linkage" from the perspectives of medicine, medical insurance and medical treatment to promote the development of innovative rare disease industries.
-
New: Expert consensus on the centralized procurement of antibiotic products (a total of 20 articles), with great impact
Time of Update: 2023-01-05
Expect the boots to hit the ground!!!Author: Zhang Tingjie Testimonials 2: It is recommended that medical institutions retain the original research drugs that have real clinical needs and the reference preparations for the consistency evaluation of the quality and efficacy of generic drugs issued by the national drug administration (recommendation level: strong recommendation) on the premise of giving priority to the use of selected drugs in centralized procurement.
-
6 billion! The U.S. interest in another domestically produced PD-1 was sold
Time of Update: 2023-01-05
The maximum total transaction amount is about 6 billion RMBSlightly different from the common drug authorization transaction, this transaction sets up a VAM repurchase clause:After the third anniversary of Fosun Pharma's first commercial sale of slilumab, Henlius has the right to repurchase the relevant license rights for a consideration of three times the sales amount in the past one year, with a minimum of US$250 million.
-
From the ranking of hospital diagnosis and treatment and drug sales data in various provinces, look at the enterprise sales plan in 2023
Time of Update: 2023-01-05
Among them, Guangdong ranks first in the country with 189 million person-times, Zhejiang ranks second with about 149 million person-times, and the number of diagnosis and treatment in Shandong, Sichuan, Jiangsu, Henan and Sichuan provinces is more than 120 million, which is not only related to the population base of each province, but also related to the medical resources and service capacity of each province.
-
TCR-T therapy heats up, see how domestic and foreign cutting-edge enterprises break the TCR-T dilemma
Time of Update: 2023-01-05
The company's innovative technology platform fuses TCR targeting tumor antigens with immune effector domains that bind to CD3 receptors on the surface of T cells, which allows TCR to recognize intracellular cancer antigens with high affinity, which is expected to break through the limitations of existing antibody drugs and increase the number of identifiable targets from 10% to 90% "cold tumors" ImmunoScape ImmunoScapeOn September 20, preclinical biotech company ImmunoScape announced the completion of a new $14 million funding round.
-
Has invested in innovative projects such as Ascentage and Zhenzhen, and won 5 new drugs, what kind of companies does this institution favor when investing?
Time of Update: 2023-01-05
Since the launch of the Science and Technology Innovation Board, the marketization of valuation has become more and more obvious, promoting new discoveries in the value of the biomedical industry, and also testing the insight of investment institutions into the future development of enterprises and their forward-looking judgment on corporate value.
-
Four departments announced: 45 anticancer drugs and 19 rare disease drugs tax reduction
Time of Update: 2023-01-05
According to the announcement, from December 1, the new batch of anticancer drugs and rare disease drugs will implement the relevant value-added tax policy, and the drugs that enter the list will be subject to value-added tax at a rate of 3%, and the validity period will be three years.
